Torres, M JRomano, ACelik, GDemoly, PKhan, D AMacy, EPark, MBlumenthal, KAberer, WCastells, MBarbaud, AMayorga, CBonadonna, P2024-01-232024-01-232017-03-13http://hdl.handle.net/10668/2681http://hdl.handle.net/20.500.12105/17296Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In this review, we highlight both the differences and the similarities between the European and U.S.engVoRhttp://creativecommons.org/licenses/by/4.0/DrugHypersensitivityAllergyDiagnosisSkin testIn vitro testIgET-cellsDrug provocation testSensitizationUnit StatesEuropeAnafilaxiaEvaluación de MedicamentosHipersensibilidad a las drogasGrupos étnicosHumanosSalud públicaPruebas cutáneasEstados UnidosEuropaAnaphylaxisDrug EvaluationDrug HypersensitivityEthnic GroupsHumansPublic HealthSkin TestsUnited StatesEuropeAttribution 4.0 International2829341510.1186/s13601-017-0144-02045-7022Clinical and Translational Allergyopen access